Literature DB >> 24067604

Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China: a retrospective study.

Mei Lan Huang1, Xi Tao Xu1, Jun Shen1, Yu Qi Qiao1, Zhang Han Dai1, Zhi Hua Ran2.   

Abstract

OBJECTIVES: The objectives of this retrospective study were to assess the prevalence of HBV and HCV infection in Chinese IBD patients, identify potential risk factors of the infection in this population, and discuss the prevalence of HBV and HCV in the general Chinese population.
METHODS: A total of 714 IBD patients who had been investigated for HBV and/or HCV infection were consecutively enrolled in the study. Clinical and laboratory data on IBD and hepatitis infection were collected. A control group of 22,373 healthy individuals was also included in the study.
RESULTS: Present and past HBV infection was found in 40.62% of IBD patients (ulcerative colitis: HBsAg+, 5.68%; anti-HBc+, 41.64%; Crohn's disease: HBsAg+, 5.29%; anti-HBc+, 39.80%;), and 27.58% of the non-IBD group (HBsAg+, 5.52%; anti-HBc+, 27.58% [P = 0.00]). HCV infection was found in 0.42% of IBD patients and 0.36% of the non-IBD group (P=0.80). One hundred and fifty-four of the IBD patients (21.57%) had been effectively vaccinated for HBV. In a multivariate analysis, age, family history of hepatitis B, and IBD-related admission were significantly related to HBV infection in IBD patients. Potential risk factors for HCV were not analyzed due to the limited number of HCV-positive patients in the study.
CONCLUSIONS: Prevalence of HBV infection in IBD patients was higher than that in the non-IBD patients, whereas prevalence of HCV infection was similar to that of the non-IBD group. Effective vaccination for HBV was present in only a small proportion of IBD patients.
© 2013.

Entities:  

Keywords:  Crohn's disease; Hepatitis B; Hepatitis C; Inflammatory bowel disease; Ulcerative colitis

Mesh:

Substances:

Year:  2013        PMID: 24067604     DOI: 10.1016/j.crohns.2013.08.017

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  16 in total

Review 1.  Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy.

Authors:  Pilar López-Serrano; Elsa de la Fuente Briongos; Elisa Carrera Alonso; Jose Lázaro Pérez-Calle; Conrado Fernández Rodríguez
Journal:  World J Hepatol       Date:  2015-03-27

Review 2.  Emerging biologics in inflammatory bowel disease.

Authors:  Heyson Chi-Hey Chan; Siew Chien Ng
Journal:  J Gastroenterol       Date:  2016-11-10       Impact factor: 7.527

Review 3.  What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?

Authors:  Gianluca Andrisani; Alessandro Armuzzi; Manuela Marzo; Carla Felice; Daniela Pugliese; Alfredo Papa; Luisa Guidi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-08-06

Review 4.  Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease.

Authors:  Stefano Sansone; Maria Guarino; Fabiana Castiglione; Antonio Rispo; Francesco Auriemma; Ilaria Loperto; Matilde Rea; Nicola Caporaso; Filomena Morisco
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

Review 5.  Prevention of Hepatitis B reactivation in the setting of immunosuppression.

Authors:  Venessa Pattullo
Journal:  Clin Mol Hepatol       Date:  2016-06-13

6.  Cholelithiasis and the risk of liver cancer: results from cohort studies of 134,546 Chinese men and women.

Authors:  Emily Vogtmann; Xiao-Ou Shu; Hong-Lan Li; Wong-Ho Chow; Gong Yang; Bu-Tian Ji; Hui Cai; Chang Yu; Yu-Tang Gao; Wei Zheng; Yong-Bing Xiang
Journal:  J Epidemiol Community Health       Date:  2014-02-26       Impact factor: 3.710

Review 7.  Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment.

Authors:  Georgios Axiaris; Evanthia Zampeli; Spyridon Michopoulos; Giorgos Bamias
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

8.  Prevalence of hepatitis B and clinical outcomes in inflammatory bowel disease patients in a viral-endemic region.

Authors:  Heyson C H Chan; Vincent W S Wong; Grace L H Wong; Whitney Tang; Justin C Y Wu; Siew C Ng
Journal:  BMC Gastroenterol       Date:  2016-08-22       Impact factor: 3.067

Review 9.  Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication).

Authors: 
Journal:  Intest Res       Date:  2018-04-30

10.  Serology of Viral Infections and Tuberculosis Screening in an IBD Population Referred to a Tertiary Centre of Southern Italy.

Authors:  Marco Ardesia; Giuseppe Costantino; Placido Mondello; Angela Alibrandi; Walter Fries
Journal:  Gastroenterol Res Pract       Date:  2017-09-17       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.